

 modality.ai



# Analytical validation of Canonical Timing Alignment (CTA) and other timing-related speech biomarkers in Amyotrophic Lateral Sclerosis (ALS) extracted automatically using a remote patient monitoring platform

Jackson Liscombe, Reva Bajjuri, Hardik Kothare, **Vikram Ramanarayanan**


## Motivation & Goals




## Methods



## Data



## Findings



## Summary



# Acknowledgements



This work was supported by the **NIH NIDCD grant R42DC019877**.

We thank our collaborators at **EverythingALS** and the **Peter Cohen Foundation** for participant recruitment and data collection.



# Motivation & Goals



- Several timing-related speech-based biomarkers of ALS have been validated both clinically and analytically (Barnett et al., ALSFTD 2021):

speaking duration

percentage pause time

articulation rate

articulation duration

speaking rate

- Past research has shown the clinical usefulness of canonical timing alignment (CTA) in ALS in terms of responsiveness of bulbar decline and listener effort

# What is Canonical Timing Alignment (CTA)?




- Given two word-segmented utterances
  - Segment each into **sub-word frames (30ms)**.
  - Calculate the difference using **Levenshtein edit distance**, as the minimum number of frame insertions, substitutions, and deletions needed to align
  - Convert to **percentage**:  
$$(\text{max\_length} - \text{edit\_distance}) / \text{max\_length} * 100$$

# CTA captures cohort differences and is strongly correlated with listener effort



Observed **significantly different CTA values** on 2,174 SITs between cohorts, as determined by Mann Whitney tests ( $p < 0.00001$ ):


- **Bulbar: 66.71%**
- **pre-Bulbar: 77.31%**
- **Control: 80.72%**



**CTA (y-axis) vs Listener Effort (x-axis). Correlation at -0.679**



# CTA tracks ALS longitudinal progression



## Bulbar Onset

Slope =  $-0.1712$  % points / week

Time to detect change  $> SE$  = 4 weeks

Time to detect a clinically-important change  $> 1$  point on ALSFRS-R speech score = **4 weeks**

## Non-Bulbar Onset

Slope (after accounting for learning effects) =  $-0.0793$  % points / week

Time to detect change  $> SE$  = 5 weeks

Time to detect a clinically-important change  $> 1$  point on the ALSFRS-R speech score = **9 weeks**



# Research Question

Is CTA extracted from reading tasks administered through a multimodal dialog agent **analytically valid** ?






# Modality's Assessment Platform

Virtual Guide



Tina

Multimodal



Metrics


- Speech
- Language
- Facial
- Limb
- Cognitive
- Eye gaze
- Activities of daily living
- Patient Report of Problems™

# Data



- **Bamboo Passage**, collected in collaboration with EverythingALS
- Selected **1 session from 30 participants, 10 each from 3 cohorts**:
  - Bulbar onset patients, pre-Bulbar onset patients, controls
- **Three methods of deriving metrics**:
  - From hand word alignments from one human annotator (H1)
  - From hand word alignment of a second human annotator (H2)
  - Automatically, including using Montreal Forced Aligner

# Methods: Annotation



Annotated word and non-word boundaries using Praat.

# Methods: CTA Calculation



- Given two word-segmented utterances
  - Segment each into **sub-word frames (30ms)**.
  - Calculate the difference using **Levenstein edit distance**, as the minimum number of frame insertions, substitutions, and deletions needed to align
  - Convert to **percentage**:  
$$(\text{max\_length} - \text{edit\_distance}) / \text{max\_length} * 100$$

# Methods: Analytic Validation Statistics



- The accuracy of each metric was assessed using:
  - Spearman rank correlation,
  - Mann-Whitney U tests,
  - mean absolute error (MAE),
  - percent error (PE), where  $PE = MAE / (H1\_max - H1\_min)$ .
- The same was done for the H1 and H2 datasets to evaluate inter-annotator agreement.

# Methods: Clinical Validation Statistics



- We analyzed the effect of MAE on clinical validity by:
  - First running a **Kruskal-Wallis H test** with all cohorts together using the H1 dataset.
  - If significant, we ran Dunn's test for each cohort pair, and **Cohen's d to calculate effect size**.
  - If **Cohen's d > 0.8**, this would indicate that this metric has promise of being clinically relevant.


# Findings: H1 vs H2



metric name	Spearman coefficient	Spearman p-value	Mann Whitney U p-value	MAE	PE
speaking duration	1	0.00E+00	0.888	0.07 seconds	0.15%
speaking rate	0.996	2.84E-30	0.807	2.51 words/second	1.90%
CTA	0.924	3.08E-13	0.329	1.48 percentage pts	3.83%
articulation rate	0.976	3.49E-20	0.483	5.23 words/second	4.02%
articulation duration	0.987	8.03E-24	0.326	1.35 seconds	4.75%
percentage pause time	0.939	1.82E-14	0.016	3.17 percentage pts	13.09%

**CTA was reliable between the two human annotators. Note that percentage pause time would benefit from how certain non-speech events were annotated.**

# Findings: H1 vs H2, CTA scatter plot



We observe excellent correlation between CTA computed off the alignments performed by the two human annotators.




# Findings: H1 vs AUTO



metric name	Spearman coefficient	Spearman p-value	Mann Whitney U p-value	MAE	PE
speaking duration	0.999	4.76E-40	0.739	0.40 seconds	0.91%
speaking rate	0.991	4.53E-26	0.785	2.81 words/minute	2.13%
articulation duration	0.976	3.73E-20	0.751	0.63 seconds	2.22%
articulation rate	0.969	1.28E-18	0.684	4.52 words/minute	3.48%
percentage pause time	0.898	1.69E-11	0.947	1.40 percentage pts	5.77%
CTA	0.775	5.00E-07	0.333	3.62 percentage pts	9.34%

**Here we see that CTA showed the highest percent error of all the automated metrics, though the statistics still show significant correlation.**

# Findings: H1 vs AUTO, CTA scatter plot



# Summary



- The CTA metric was analytically validated, as were other speech timing related metrics.
- This is important because we have found that CTA is better at clinically tracking ALS progression than are those other standardized speech timing metrics.



# Self-driven Neurological Assessments

**Modality.AI Inc.**

149 New Montgomery St, 4th Floor, San Francisco, CA 94105

**Vikram Ramanarayanan, Chief Science Officer**

vikram.ramanarayanan@modality.ai